News & Events

Pharmaceuticals Limited (ASX: CXS) announced today that Greg Collier, PhD, Chief Executive Officer and Managing Director will present a company update at the BIO CEO & Investor Conference in the Duke of Windsor Room of the Waldorf Astoria Hotel in New York City on Tuesday, 15 February 2011 at 8:00 a.m. Eastern Time in the U.S.

Dr Collier will provide an update on the development of omacetaxine and upcoming milestones. ChemGenex is preparing a New Drug Application (NDA) for omacetaxine in CML patients who have failed therapy with two or more tyrosine kinase inhibitors (TKIs) based on data from its two pivotal trials, and anticipates submission to the U.S. Food and Drug Administration (FDA) in H2 2011. Reflecting the alignment of U.S. and European regulatory strategies for omacetaxine, ChemGenex has withdrawn the prior NDA for omacetaxine.

Dr Collier’s presentation, being the company’s corporate overview, can be accessed from the company’s website; http://www.chemgenex.com/investors/presentations

ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. A New Drug Application is in preparation for submission to the U.S. Food and Drug Administration in H2 2011 for omacetaxine in CML patients who are resistant to, or have failed two or more currently approved tyrosine kinase inhibitors. A parallel Marketing Authorisation Application is in preparation for submission to the European Medicines Agency in H2 2011. ChemGenex has established a corporate alliance with Hospira Inc. to develop and commercialize omacetaxine in Europe, the Middle East and parts of Africa, and is seeking to establish commercial partnerships in the rest of the world. ChemGenex plans to commercialize omacetaxine itself in North America. ChemGenex trades on the Australian Securities Exchange under the symbol "CXS". For additional information on ChemGenex Pharmaceuticals, please visit the Company’s website at http://www.chemgenex.com.

OMAPRO™ is a trademark of ChemGenex Pharmaceuticals Limited.

Dr. Greg Collier (CEO and Managing Director) Cell Australia +61 419 897501

Cell (USA): +1 650 200 8145

Rebecca Wilson

Buchan Consulting

Cell +61 (0)417 382 391

Dr. Andrew McDonald

LifeSci Advisors

Cell: +1.415.205.0591

Email: [email protected]

Certain statements made herein (including for this purpose sites to which a hyperlink has been provided) that use the words "estimate", "project", "intend", "expect", "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company's technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company's technology, the market for the company's products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management's current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.